ArticleNano research2025
Incidental vs. Engineered Nanoparticles in Alzheimer's and Parkinson's Disease: Pathological Pathways and Therapeutic Interventions.
Article in Nano research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The protein corona at the nano-bio interface: the need for standardized methodology and opportunities for neurodegenerative disease intervention.RSC advances · 2026Review
- Quantum Dots: Catalysts for a New Era of Precision Medicine and Biomedical Innovation.Journal of fluorescence · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Nanoparticles (NPs) play dual roles in neurodegeneration. Incidental NPs, generated unintentionally from environmental and industrial sources, are linked to oxidative stress, neuroinflammation, and disruption of the blood-brain barrier in Alzheimer's disease (AD) and Parkinson's disease (PD). Engineered NPs are designed for diagnosis and therapy using nanobodies, nanozymes, and other engineered nanoparticle (ENP) platforms that enable targeted delivery, modulation of neuroimmune pathways, and interference with pathological protein aggregation. This review aligns source-based classes (incidental versus engineered) with composition-based families (metal-based, carbon-based, and polymeric or inorganic), and summarizes routes of exposure, mechanistic toxicology, and engineered interventions relevant to AD and PD. We also evaluate current limitations, including biocompatibility, relevance to chronic exposure, and clinical benchmarking, and we outline priorities for translating nanotechnology into practical diagnostics and therapeutics for neurodegenerative disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.